November 2, 2011 - Mantle Cell Lymphoma Update
- Mantle cell lymphoma
- Current and emerging therapies for mantle cell lymphoma
- Role of clinical trials in the continuing improvement of mantle cell lymphoma treatment outcomes
- Possible side effects of treatment and their management
John P. Leonard, MD
The Richard T. Silver Distinguished Professor
of Hematology and Medical Oncology
Weill Cornell Medical College
New York, NY
Questions Asked by the NHL Community
- Can a patient who is 72 years old receive a stem cell transplant?
- Could Dr. Leonard comment on personalized vaccines?
- Has Dr. Leonard participated in any of the trials for personalized vaccines? And how optimistic are they actually looking?
- After a patient is in remission, is there anything that should be done as far as eating, drinking, medications to help ensure that the lymphoma will not come back?
- After a reoccurrence of mantle cell lymphoma only in the throat, does it make sense to use localized radiation treatment for that particular spot as opposed to using bendamustine (Treanda®)and rituximab (Rituxan®) or some combination?
- Other than a stem cell transplant, are there any other treatment options available to achieve a complete remission?
- How long can a patient continue taking maintenance treatment with Rituxan?
- Is this disease hereditary?
- What is the life expectancy and the chances of relapsing after a stem cell transplant?
- Is watch and wait a viable treatment option for relapse?
- What is Dr. Leonard's experience with iodine131-tositumomab (Bexxar®)?
Sponsors and Supporters
This program was sponsored by The Leukemia & Lymphoma Society and supported by a grant from Millennium: The Takeda Oncology Company.